



PRESS RELEASE

## **SARomics Biostructures signs exclusive distribution agreement with Carna Biosciences**

**Lund, Sweden and Kobe, Japan, August 25, 2016 - SARomics Biostructures AB today announced that the company has entered into a collaborative distributorship agreement with Carna Biosciences, Inc. to provide its crystallography and protein structure determination services in Japan.**

Under the terms of the agreement, Carna Biosciences will be the exclusive distributor for SARomics' co-crystallography services on the Japanese market. The agreement also encompasses non-exclusive distribution in China, Korea, Canada and the state of California.

The crystallography services are used to increase the information content and to accelerate the development of pharmaceuticals. A co-crystal of a certain protein with the customer's compound generated from their drug discovery research is analyzed by X-ray crystallography to determine the three-dimensional structure of the complex. This information reveals how the compound interacts with the protein and is used by pharmaceutical companies and other customers in the design of new and improved compounds.

"We feel privileged to start to work with SARomics having world class expertise and technology in the field of crystallography and protein structure determination. We hope our collaboration with SARomics will make our support for drug discovery of our clients much stronger and of higher quality than ever," said Norio Aikawa, Director of the board and head of Sales and Marketing, Drug Discovery Support Business at Carna Biosciences.

"We have built a global reputation for our structure-based drug design skills and technology platform and we are currently supporting clients in Europe and USA to pursue their drug discovery objectives. We are honored that our work has been recognized by Carna Bioscience and that they wish to introduce our services in Japan and other territories," said Dr. Björn Walse, Founder and CEO at SARomics Biostructures.

The agreement is expected to have a modest influence on Carna's business performance forecast of FY2016.

**SAROMICS BIOSTRUCTURES AB** is a technology-driven research company located in the Medicon Valley region of southern Sweden. SARomics' advanced structural biology platform and expertise in structure-based drug design is applied to a number of innovative early stage drug discovery projects as well as in fee for service projects for clients. The company's extensive portfolio of FastLane™ off-the-shelf protein structures enables faster project execution, substantially accelerating the drug discovery process. SARomics is currently a collaborative partner in several international research efforts and has been awarded EU financing for three consecutive drug discovery research projects among which TAKTIC and KINOMED are kinase drug discovery projects for oncology indications. For further information please visit [www.saromics.com](http://www.saromics.com).

**CARNA BIOSCIENCES, Inc** is a biopharmaceutical company focused on the discovery and development of proprietary kinase inhibitor drugs to treat serious unmet medical needs. By leveraging expertise and experiences accumulated through its own drug discovery efforts, Carna has established extensive distribution channels as a reliable service provider, and has proven to be an excellent supplier of high-quality drug discovery support services, including crystallography services, to scientists worldwide. Carna Biosciences was founded in Kobe, Japan, in 2003 as a spinoff of Japan Organon (Nippon Organon KK). Carna is a publicly traded company in the JASDAQ of the Tokyo Stock Exchange with securities code, 4572. For further information, please visit [www.carnabio.com/english/](http://www.carnabio.com/english/).